<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yu Q</submitter><funding>Guangzhou Science and Technology Plan Project</funding><funding>the Guangzhou Science and Technology Plan Project</funding><funding>Guangzhou Municipal Institute Enterprise Joint Funding Project</funding><funding>Science and Technology Project of Foshan</funding><funding>Natural Science Foundation of Guangdong Province</funding><pagination>50</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11247778</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Estrogen receptor-positive (ER+) breast cancer accounts for two-thirds of all breast cancers, and its early and late recurrences still threaten patients' long-term survival and quality of life. Finding candidate tumor antigens and potential therapeutic targets is critical to addressing these unmet needs.&lt;h4>Method&lt;/h4>The isobaric tags for relative and absolute quantitation (iTRAQ) proteomic analysis was employed to identify the differentially expressed proteins (DEPs) between ER + breast cancer and corresponding adjacent normal tissue. Candidate DEPs were screened by bioinformatic analyses, and their expression was confirmed by immunohistochemical (IHC) staining and western blot. A series of in vitro experiments, including wound healing assay, colony formation, and cell</pubmed_abstract><journal>Clinical proteomics</journal><pubmed_title>ESF1 and MIPEP proteins promote estrogen receptor-positive breast cancer proliferation and are associated with patient prognosis.</pubmed_title><pmcid>PMC11247778</pmcid><funding_grant_id>202103000051</funding_grant_id><funding_grant_id>202102010101</funding_grant_id><funding_grant_id>2220001004797</funding_grant_id><funding_grant_id>SL2024A03J00312</funding_grant_id><funding_grant_id>2024A04J9904</funding_grant_id><funding_grant_id>2019A1515110044</funding_grant_id><pubmed_authors>Qu C</pubmed_authors><pubmed_authors>Yang Z</pubmed_authors><pubmed_authors>Chen P</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Zhang K</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Yu Q</pubmed_authors><pubmed_authors>Liang J</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Yang A</pubmed_authors><pubmed_authors>Sun H</pubmed_authors></additional><is_claimable>false</is_claimable><name>ESF1 and MIPEP proteins promote estrogen receptor-positive breast cancer proliferation and are associated with patient prognosis.</name><description>&lt;h4>Background&lt;/h4>Estrogen receptor-positive (ER+) breast cancer accounts for two-thirds of all breast cancers, and its early and late recurrences still threaten patients' long-term survival and quality of life. Finding candidate tumor antigens and potential therapeutic targets is critical to addressing these unmet needs.&lt;h4>Method&lt;/h4>The isobaric tags for relative and absolute quantitation (iTRAQ) proteomic analysis was employed to identify the differentially expressed proteins (DEPs) between ER + breast cancer and corresponding adjacent normal tissue. Candidate DEPs were screened by bioinformatic analyses, and their expression was confirmed by immunohistochemical (IHC) staining and western blot. A series of in vitro experiments, including wound healing assay, colony formation, and cell</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-04-25T19:12:54.27Z</modification><creation>2025-04-06T07:53:50.384Z</creation></dates><accession>S-EPMC11247778</accession><cross_references><pubmed>39004717</pubmed><doi>10.1186/s12014-024-09502-8</doi></cross_references></HashMap>